Lessons learnt from existing gene therapy trials

This tool is associated with the following interest areas: Industry, Sites

As Gene Therapy is relatively new to the Duchenne community we are keen to learn from experiences in other diseases. This downloadable PDF covers some lessons we have learnt from existing Gene Therapy trials regarding pharmacy, risk assessment, R&D and costing. The document has been drafted by Newcastle, reviewed by GOSH and approved by the chair of the Trust Genetic Modification Safety Committee.  

Link to PDF here.



We have placed cookies on your computer to help make this website better. For more information please click here

By continuing to use this site or closing this panel, we'll assume you're OK to continue. You can view our full privacy policy here